In This Section      
 

Search Results

A total of 45 matching records were found.

A085
A Pilot Trial of AVD in addition to Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10061
A Phase 1 Study of MK-3475 (pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors (NCI#10061)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10070
Phase 1/2 study of navitoclax plus vistusertib in patients with relapsed small cell lung cancer (SCLC) and other solid tumors (ETCTN10070)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10129
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors (ETCTN10129)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10131
A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel (ETCTN10131)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10170
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies (ETCTN10170)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN9952
9952 Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

G0264
G0264 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J12106
A Phase II Trial of Reduced Intensity Conditioning of Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplant for High-risk Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J12114
Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advanced BRAF V600-Mutation Positive Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J13101
J13101 "A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors".

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1353
A Phase II Study of Epigenetic Therapy with Azacitidine and Entinostat with Concurrent Nivolumab in Subjects with Metastatic Non-Small Cell Lung Cancer.

Sites: Johns Hopkins Bayview Medical Center, Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1414
Neoadjuvant Nivolumab, or Nivolumab in combination with Ipilimumab, in Resectable Non-Small-Cell Lung Cancer

Sites: Johns Hopkins Bayview Medical Center, Johns Hopkins Kimmel Cancer Center in Baltimore

J1480
My Pathway: MY PATHWAY: AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB, AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS(Protocol Number: ML28897/PRO 02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15117
J15117 - Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15195
J15195 - A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15221
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (NCI# 9844)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15222
J15222: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1581
STM-03: Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16108
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1615
A Phase 1/2 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors (Sponsor Protocol Number: D419NC00001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1641
(CA018-001) A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1658
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Extensive Stage Small Cell Lung Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1677
J1677- A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1681
A Phase I Dose Escalating Trial of Mistletoe Extract in Patients with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1688
Regenerative Medicine to Restore Normal Hematopoiesis in Aplastic Anemia

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1705
Study INCB 01158-101 (formerly known as CX-1158-101) Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17121
A Phase 1, Open-Label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 Monotherapy and SNDX-6352 in Combination with Durvalumab in Patients with Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17122
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms (CP-MGD013-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17158
Overcoming Checkpoint Inhibitor Resistance with Epigenetic Therapy in Urothelial Cancer (GU-114)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17168
A Phase 1b Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients with Resectable Solid Tumor Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17191
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, Ilaris® (canakinumab) or Mekinist® (trametinib) (CPDR001X2103)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1778
An Open-label, Phase I, Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors (sponsor protocol MS100015-0019)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1791
A Phase II, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma (CNIR178X2201)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1798
J1798: A Phase 2 Clinical Trial of Entinostat in Combination with Nivolumab for Patients with Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1804
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Johns Hopkins Bayview Medical Center

J18102
J18102 - Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibition

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1825
A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors (CA224-048)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1826
Studying the Pathologic and Immunologic Response after Ablative Radiation in Stage I Non-Small Cell Lung Cancer (SPARC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1885
Using 4R care sequences for lung cancer care: 4R is "Right Information and Right Care for the Right Patient at the Right time."

Sites: Johns Hopkins Bayview Medical Center

NCTNA081105
A081105 Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

NCTNA151216
A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

NCTNE4512
E4512 A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Johns Hopkins Bayview Medical Center

NCTNEA5142
EA5142 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Sites: Johns Hopkins Bayview Medical Center, Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

PAAML1331
AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore